PDGFRA and meningioma: In this study, we evaluated the efficacy of the ponatinib in MGM cells and found that ponatinib demonstrated potent anti-meningioma effects in vitro and in vivo presumably through PDGFRA/B inhibition and mitochondrial dysfunction.